UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549
	SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

(Name of Issuer)

 

(Title of Class of Securities)

 

(CUSIP Number)

 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

This filing is being made to amend the Schedule 13D previously filed by Samuel S. Lee on August 20, 2007 solely to amend and restate Item 2(a)-(c).  There have been no other changes to the information previously reported in the August 20, 2007 Schedule 13D filing.

 

Item 2.	Identity and Background
(a)-(c)
This statement on Schedule 13D (the “Statement”) is filed by Samuel S. Lee, whose business address is c/o Alta Hospitals System, LLC, 11500 W. Olympic Blvd., Suite 502, Los Angeles, CA  90064.  Mr. Lee is the Chief Executive Officer of such company.  In addition, Mr. Lee was promoted to the position of Chief Executive Officer of the Issuer as approved by the Issuer’s Board of Directors on March 19, 2008.

 

2

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	April 16, 2008
	Date
	/s/ Samuel S. Lee
	Signature
	Samuel S. Lee
	Name/Title

 

3